RESILIENCE GOVERNMENT SERVICES, INC.

PRODUCTION OF A MAB-BASED THERAPEUTIC DIRECTED AGAINST A BROAD SPECTRUM OF HIGHLY DIVERSE BOTULINUM NEUROTOXIN SEROTYPE F SUBTYPES AND DISCOVERY WORK OF MAB AGAINST BOTULINUM NEUROTOXIN SEROTYPE G.

THIS DELIVERY ORDER IS FOR TASKS ASSOCIATED WITH THE DEVELOPMENT OF US FOOD AND DRUG ADMINISTRATION LICENSED MONOCLONAL ANTIBODY COUNTERMEASURE FOR BOTULINUM NEUROTOXIN EXPOSURE.

THIS DELIVERY ORDER IS FOR TASKS ASSOCIATED WITH THE DEVELOPMENT OF US FOOD AND DRUG ADMINISTRATION LICENSED MONOCLONAL ANTIBODY COUNTERMEASURE FOR BOTULINUM NEUROTOXIN EXPOSURE.

THIS DELIVERY ORDER IS FOR RESEARCH AND DEVELOPMENT TASKS ASSOCIATED WITH DEVELOPING A US FOOD AND DRUG ADMINISTRATION LICENSED MONOCLONAL ANTIBODY COUNTERMEASURE FOR BOTULINUM NEUROTOXIN EXPOSURE.

U.S. FOOD AND DRUG ADMINISTRATION (FDA) LICENSED MONOCLONAL ANTIBODY COUNTERMEASURE FOR BOTULINUM NEUROTOXIN EXPOSURE.

PRODUCTION OF A MAB-BASED THERAPEUTIC DIRECTED AGAINST A BROAD SPECTRUM OF HIGHLY DIVERSE BOTULINUM NEUROTOXIN SEROTYPE F SUBTYPES AND DISCOVERY WORK OF MAB AGAINST BOTULINUM NEUROTOXIN SEROTYPE G.

DEVELOPMENT OF LNA14 ANALYTICAL METHODS AND UPSTREAM AND DOWNSTREAM PROCESSES FOR MANUFACTURING, AND SCALE-UP MANUFACTURING AND RELEASE TESTING OF THE PURIFIED LNA14 PRODUCT

THIS CONTRACT WILL PROVIDE THE DEPARTMENT OF DEFENSE WITH THE ADVANCED DEVELOPMENT AND MANUFACTURING CAPABILITY TO RAPIDLY DEVELOP, APPROVE AND MANUFACTURE MEDICAL COUNTERMEASURES.

THIS REQUIREMENT IS FOR THE DEVELOPMENT OF A U.S. FOOD AND DRUG ADMINISTRATION LICENSED MONOCLONAL ANTIBODY COUNTERMEASURE FOR BOTULINUM NEUROTOXIN EXPOSURE.

THIS DELIVERY ORDER IS FOR TASKS ASSOCIATED WITH THE DEVELOPMENT OF US FOOD AND DRUG ADMINISTRATION LICENSED MONOCLONAL ANTIBODY COUNTERMEASURE FOR BOTULINUM NEUROTOXIN EXPOSURE.

PRODUCTION OF A MAB-BASED THERAPEUTIC DIRECTED AGAINST A BROAD SPECTRUM OF HIGHLY DIVERSE BOTULINUM NEUROTOXIN SEROTYPE F SUBTYPES AND DISCOVERY WORK OF MAB AGAINST BOTULINUM NEUROTOXIN SEROTYPE G.

THIS REQUIREMENT IS FOR THE DEVELOPMENT OF A U.S. FOOD AND DRUG ADMINISTRATION LICENSED MONOCLONAL ANTIBODY COUNTERMEASURE FOR BOTULINUM NEUROTOXIN EXPOSURE.

U.S. FOOD AND DRUG ADMINISTRATION (FDA) LICENSED MONOCLONAL ANTIBODY COUNTERMEASURE FOR BOTULINUM NEUROTOXIN EXPOSURE CONTRACT EFFORT.

U.S. FOOD AND DRUG ADMINISTRATION (FDA) LICENSED MONOCLONAL ANTIBODY COUNTERMEASURE FOR BOTULINUM NEUROTOXIN EXPOSURE, CLINICAL DEVELOPMENT PHASE 3 STUDY

U.S. FOOD AND DRUG ADMINISTRATION (FDA) LICENSED MONOCLONAL ANTIBODY COUNTERMEASURE FOR BOTULINUM NEUROTOXIN EXPOSURE EFFORT.

PRODUCTION OF A MAB-BASED THERAPEUTIC DIRECTED AGAINST A BROAD SPECTRUM OF HIGHLY DIVERSE BOTULINUM NEUROTOXIN SEROTYPE F SUBTYPES AND DISCOVERY WORK OF MAB AGAINST BOTULINUM NEUROTOXIN SEROTYPE G.

PRODUCTION OF A MAB-BASED THERAPEUTIC DIRECTED AGAINST A BROAD SPECTRUM OF HIGHLY DIVERSE BOTULINUM NEUROTOXIN SEROTYPE F SUBTYPES AND DISCOVERY WORK OF MAB AGAINST BOTULINUM NEUROTOXIN SEROTYPE G.

DEVELOPMENT OF LNA14 ANALYTICAL METHODS AND UPSTREAM AND DOWNSTREAM PROCESSES FOR MANUFACTURING, AND SCALE-UP MANUFACTURING AND RELEASE TESTING OF THE PURIFIED LNA14 PRODUCT

CLINICAL DEVELOPMENT PHASE 3 STUDY

CGMP DS CONFIRMATION RUN(S)

CLINICAL DEVELOPMENT PHASE 3 STUDY

DS PROCESS CHARACTERIZATION

CLINICAL DEVELOPMENT PHASE 3 STUDY

CGMP DS CONFIRMATION RUN(S)

DS PROCESS CHARACTERIZATION

CGMP DS CONFIRMATION RUN(S)

CLINICAL DEVELOPMENT PHASE 3 STUDY

CGMP DS CONFIRMATION RUN(S)

BOTMAB CLINICAL DEVELOPMENT PHASE 2 STUDY

DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEVELOPMENT PHASE 3, AND STORAGE/STABILITY FOR THE PROGRAM WITH ULTIMATE GOAL OF U.S. F.D.A. LICENSURE OF BONT MAB G03-52-01 DRUG PRODUCT.

DS PROCESS CHARACTERIZATION

INCREMENTALLY FUND PROGRAM MANAGEMENT CLIN 0001 AND CLIN 0003 CGMP DS CONFIRMATION RUN ON BOTMABS PROJECT.

ADM ESTABLISHMENT & COMMISSIONING

ADM ESTABLISHMENT & COMMISSIONING

CLINICAL DEVELOPMENT PHASE 2 STUDY

DS PROCESS CHARACTERIZATION

U.S. FOOD AND DRUG ADMINISTRATION (FDA) LICENSED MONOCLONAL ANTIBODY COUNTERMEASURE FOR BOTULINUM NEUROTOXIN EXPOSURE

CLINICAL DEVELOPMENT PHASE 2 STUDY

CLINICAL DEVELOPMENT PHASE 2 STUDY

ADM ESTABLISHMENT & COMMISSIONING